CTLA4 and Miyoshi myopathy: A multi-institutional retrospective study of 225 Japanese patients with MM evaluated anti-PD-1 monotherapy or anti-PD-1 + anti-CTLA-4 combination therapy with or without radiotherapy and found no survival benefit with RT in either ICI regimen (72).